IMPROVEMENTS IN MAJOR CLINICAL EVENTS IN CHILDREN TREATED WITH TRIHEPTANOIN FOR LONG-CHAIN FATTY ACID OXIDATION DISORDERS (LC-FAOD)
Kathryn Ray(Ultragenyx Pharmaceutical (United States)), Jerry Vockley(Pittsburgh Public Schools), Xiaoxiao Lu(Ultragenyx Pharmaceutical (United States)), Laura Rosa Pisani(Regenxbio (United States))
Cited by 0
Related Papers
Phenylalanine hydroxylase deficiency: diagnosis and management guideline
|Genetics in Medicine|2014|718
Effects of Diet and Physical Activity Interventions on Weight Loss and Cardiometabolic Risk Factors in Severely Obese Adults
|JAMA|2010|554
Targeted disruption of mouse long-chain acyl-CoA dehydrogenase gene reveals crucial roles for fatty acid oxidation
|Proceedings of the National Academy of Sciences|1998|254
AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders
|Nature Communications|2019|252